RxSight(US:RXST) Prnewswire·2025-09-06 13:00Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed challenges affecting the company's performance [3][4]. Group 1: Allegations Against RxSight - The complaint alleges that RxSight and its executives made false or misleading statements regarding the company's sales and utilization, overstated product demand, and failed to meet previously issued financial guidance for fiscal year 2025 [3]. - Specific issues cited include "adoption challenges" and structural problems leading to declines in sales and utilization, which were not disclosed to investors [3]. Group 2: Financial Impact - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, showing significant declines in LDD sales, LAL utilization, and overall revenue, along with a lowered full-year guidance by approximately $42.5 million at the midpoint [4]. - Following this announcement, RxSight's stock price dropped by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, amid unusually high trading volume [4]. Group 3: Legal Proceedings - Investors who suffered losses in RxSight are encouraged to contact Faruqi & Faruqi to discuss their legal rights, with a deadline of September 22, 2025, to seek the role of lead plaintiff in the class action lawsuit [1][5]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [5].